Skip to main content
Stock Expert AI
Biotech Brief INTERMEDIATE ✨ AI Enhanced

Novo Nordisk NVO reports Nov. 4: a low P/E, but profit swings by the quarter

9 min read Data as of 2 sources
NVO$40.00+2.20%Today, Nov 20, 2026: 87/100

AI-generated editorial content. For informational purposes only. Not financial advice.

NVO — Journal cover

Stock Expert AI data cover: figures from Financial Modeling Prep. Photo credit and licence on the image

Novo Nordisk (NVO) reports earnings on Nov. 4, 2026, with its stock at 40 USD and a trailing price-to-earnings ratio (P/E, the share price divided by a year of profit per share) of 10.15. The cheap-looking multiple sits beside a profit line that swung sharply: net income in the second quarter ended June 30, 2026 was 20.8% lower than a year earlier, even as revenue rose 2.1%. This piece looks at that gap between a low multiple and uneven earnings. Figures are current as of Oct. 30, 2026 (price) and cover quarters through June 30, 2026.

Key facts

  • Price: 40 USD on Oct. 30, 2026, up 2.20% on the latest quote. The 52-week range is 35.12-64.16 USD. Market cap is $176.43B.
  • Next report: Nov. 4, 2026. Analysts estimate EPS of 0.731 USD per US-listed share and revenue of $11.08B (in USD).
  • Last report (Aug. 5, 2026): EPS of 0.96 USD against an estimate of 0.82 USD; revenue of $12.13B against an estimate of $10.89B.
  • Second quarter ended June 30, 2026: revenue of DKK 78.49B, operating income of DKK 27.06B, net income of DKK 20.99B, diluted EPS of 4.74 DKK.
  • Same quarter a year earlier (ended June 30, 2025): revenue of DKK 76.86B, operating income of DKK 33.45B, net income of DKK 26.50B, diluted EPS of 5.96 DKK.
  • Stock Expert AI MoonshotScore V2: 92.5 (Exceptional).
Note on currency: Novo Nordisk reports its financial statements in Danish kroner (DKK). The share price, price targets and the earnings-report EPS and revenue lines are in USD, and EPS is stated per US-listed share. The two currencies are not interchangeable here.

What happened

The theme: a cheap multiple on uneven profits. A low P/E can mean the market expects earnings to fall, or it can mean the stock is simply out of favor. Investors tend to treat a low multiple with caution when the profit it is based on moves a lot from quarter to quarter. Novo Nordisk is a current example. A recent Motley Fool headline asked whether the stock's low earnings multiple and its share buybacks mark a bottom. That is a question, not an answer, and the company's own numbers show why it is hard to settle.

The second quarter, in the company's reported numbers. Revenue in the quarter ended June 30, 2026 was DKK 78.49B, 2.1% higher than the year-ago quarter. Operating income fell to DKK 27.06B from DKK 33.45B a year earlier, and net income fell 20.8%. So sales grew a little while profit dropped meaningfully. Gross margin fell to 78.2% from 83.3% a year earlier and operating margin fell to 34.5% from 43.5%; the data does not explain why. The data provided to us does not include a company release or call transcript, so we cannot quote management on the reasons. We describe only what the statements show.

The five-quarter trend. This table is included because the story is the swing in profitability, and the swing is clearest across quarters.

Quarter endedRevenue (DKK)Gross marginOperating marginNet income (DKK)Free cash flow (DKK)
June 30, 202576.86B83.3%43.5%26.50B24.51B
Sept. 30, 202574.98B76.1%31.6%20.01B30.69B
Dec. 31, 202579.14B80.9%40.1%26.89B-36.22B
March 31, 202696.82B86.0%61.6%48.56B12.04B
June 30, 202678.49B78.2%34.5%20.99B42.40B

The table shows that the March 2026 quarter was an outlier. Revenue, margins and net income all peaked, and the June quarter returned to a level closer to the other quarters. Operating margin (the share of sales left after running costs) ranged from 31.6% to 61.6% over these five quarters. Anyone judging the stock on the P/E alone is partly judging it on how much of that peak quarter sits inside the trailing 12 months.

Cash flow. Free cash flow (cash from operations minus capital spending) was DKK 42.40B in the June 2026 quarter, with operating cash flow of DKK 55.20B and capital expenditure of DKK -12.80B. Free cash flow was negative at DKK -36.22B in the quarter ended Dec. 31, 2025, when capital expenditure was DKK -43.84B. Cash flow statements show the company repurchased shares in both 2026 quarters, though not in the quarter ended Dec. 31, 2025, and paid a dividend in the March 2026 quarter but none in the June 2026 quarter. The trailing dividend yield is 4.4%.

Balance sheet. As of June 30, 2026, cash and short-term investments were DKK 44.98B against total debt of DKK 140.13B. FMP lists net debt of DKK 95.64B. Shareholders' equity was DKK 221.28B, and debt-to-equity is 0.63. The Piotroski score (a 0-9 measure of financial health) is 6, and the Altman Z score (a bankruptcy-risk gauge) is 3.77.

Why it matters for investors

Valuation against peers. On trailing figures, Novo Nordisk's P/E of 10.15 is below every large drugmaker in our peer set, and its net margin of 35.3% is higher than all of them.

CompanyP/E (trailing)Net margin
Novo Nordisk (NVO)10.1535.3%
AbbVie (ABBV)50.5815.7%
Amgen (AMGN)28.7322.9%
AstraZeneca (AZN)26.2517.7%
GSK17.1813.0%

Other trailing multiples for Novo Nordisk: price-to-sales 3.56, EV/EBITDA (enterprise value, which adds net debt to market cap, over operating earnings before depreciation) 7.15, and price-to-free-cash-flow 23.99. A gap this wide usually means the market is discounting something: lower future profit, or doubt that the strong quarter can repeat. The numbers alone do not say which.

What analysts say. Of 39 ratings, 1 is strong buy, 22 are buy, 13 are hold and 3 are sell, for a consensus of "Buy." The consensus price target averages 42.33 USD, with a median of 40.00 USD, a high of 47.00 USD and a low of 40.00 USD. The stock at 40 USD sits at the median and the low end of that range. In the last 30 days, BMO Capital maintained its Market Perform rating on Oct. 12, 2026. The FMP discounted cash flow model, an automated estimate of what future cash flows are worth today, gives 79.44 USD per share as of Nov. 1, 2026. Model outputs like this depend heavily on their inputs, so treat it as one reference point and not a forecast.

Our MoonshotScore. Stock Expert AI's MoonshotScore V2 is 92.5 (Exceptional). The pillars, scored relative to the sector, are:

  • Quality: 98. The strongest area, consistent with high margins.
  • Growth: 77. Solid, though second-quarter revenue growth was modest.
  • Valuation: 67. Above the middle, consistent with the low multiple.
  • Safety: 64. Middling, consistent with the debt load and the swing in cash flow.
  • Momentum: 51. The weakest pillar, consistent with a share price well below its 52-week high of 64.16 USD.
What could go wrong. First, the earnings base is volatile. If the strong March 2026 quarter proves to be a one-off, the trailing P/E understates how expensive the stock is on a steadier profit level. Second, margins fell back in the June quarter, and the next report will show whether that continues. Third, analyst coverage of far-out quarters is thin: the estimates for the periods ending March 30, 2027 and June 30, 2027 each come from a single analyst, so they are weak guides. Fourth, a debt balance of DKK 140.13B leaves less room for error if cash flow dips again, as it did in the December 2025 quarter.

What to watch next

  • Nov. 4, 2026 results. The estimates are EPS of 0.731 USD and revenue of $11.08B. The last report beat both estimates, so the bar for a repeat is the key question.
  • Operating margin. The June quarter margin was 34.5%. Whether the next quarter moves toward the lower or higher end of the recent range matters more than revenue alone.
  • Cash flow and capital spending. Watch whether free cash flow stays positive after the large capital outlay in the December 2025 quarter.
  • Buybacks and dividends. The cash flow statement shows how much the company returns to shareholders after the report.
  • Analyst estimate changes. Watch whether the price-target range of 40.00-47.00 USD shifts after the results.

Frequently asked questions

Q: Why does Novo Nordisk have such a low P/E ratio?

Novo Nordisk's trailing P/E is 10.15, well below AbbVie, Amgen, AstraZeneca and GSK. A low multiple can reflect market doubt that recent profits will last. Quarterly operating margin ranged from 31.6% to 61.6% over the last five quarters, so the trailing profit includes an unusually strong quarter. The data we have does not state the market's reasoning, so this is an interpretation, not a fact.

Q: When does Novo Nordisk report earnings, and what do analysts expect?

Novo Nordisk reports on Nov. 4, 2026. Analysts estimate EPS of 0.731 USD per US-listed share and revenue of $11.08B. On Aug. 5, 2026, it reported EPS of 0.96 USD and revenue of $12.13B, both above estimates.

Q: What is the analyst price target for NVO stock?

The consensus price target is an average of 42.33 USD, with a median of 40.00 USD, a high of 47.00 USD and a low of 40.00 USD. The share price was 40 USD on Oct. 30, 2026. Of 39 ratings, the consensus is "Buy." These are analyst views, not Stock Expert AI predictions, and not investment advice.

Sources: Stock Expert AI market data and MoonshotScore (our own); financial statements, estimates, ratings and price targets from FMP; the Motley Fool headline of Nov. 1, 2026 is third-party commentary used for context only.

This is educational content, not investment advice. Past performance does not guarantee future results.

What to watch next

  1. Results. The estimates are EPS of 0.731 USD and revenue of $11.08B. The last report beat both estimates, so the bar for a repeat is the key question.

NVO on Stock Expert AI

MoonshotScore 87/100 Nov 20, 2026

A 0-100 score built from five sections.

  • Quality96
  • Safety44
  • Valuation62
  • Growth82
  • Momentum61
🎯

MoonshotScore AI Ratings

Each stock is scored 0-100 on five pillars: Business Quality, Financial Safety, Valuation, Growth Durability and Momentum. A story quotes the score of the day it was written.

NVO Today, Nov 20, 2026: 87/100When published, Nov 1, 2026: 93/100

Related Tickers

NVO
earningsbiotechnology

Sources

Related Sectors & Industries

Next story

Momentum Movers Why did Regeneron stock rise? Shares jumped after a Q3 beat 8 min readREGN
👁 Editorial Transparency
🧠Content generated by AI editorial engine
👤Stock Expert AI Research is an AI editorial voice of Stock Expert AI
✅Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
🛡Financial Modeling Prep (FMP)
🕑Last updated:

Get the week's earnings in one Thursday email

The S&P 500 companies on that week's earnings calendar, each with its current MoonshotScore, plus the week's Journal research. Free, one email a week, with an unsubscribe link in every issue.

We send one confirmation email first and nothing else until you click its link (it works for 7 days). After that, the Weekly only. Your address is not sold or shared. Newsletter details · Free guide: How to read a MoonshotScore · Privacy Policy


Explore More Market Intelligence

Evidence & Sources

  • Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
  • MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). Weights are rescaled to 100 when all five pillars have data: 28.3%, 21.7%, 19.6%, 17.4% and 13.0% of the score. It reads no news-sentiment or analyst data, and it is not a probability of future returns.
  • Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
  • Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
  • This page is educational and does not constitute investment advice.
  • Numbers come from market data providers (FMP); AI writes the plain-English explanations around them, which should be verified with independent research.